

RLT-CONNECT Changing lives, one patient at a time



An online platform connecting healthcare professionals & radioisotope companies to help cancer patients in financial need access life-saving radiotheranostics


Access | Education | Hope

About the Oncidium foundation

We are a non-profit foundation fully dedicated to supporting and advancing the development of nuclear medicine therapies. Our mission is to educate, raise awareness, and support people living with cancer in their daily battle for longer and better lives.

A Global Network of Ambassadors

The foundation is composed of a wide network of Ambassadors. From all around the world, they act locally and internationally, to further support the development of radiotheranostics for cancer care.



Our Advisory Board



Dr. Alice Viana **Chair** Belgium



Venkatesh Member India



Dr. Omar Yehia Hussein **Member** Egypt



Calais
Member
United States

Dr. Jeremie



Dr. Vasko Kramer Member Chile

Radiotheranostics: Inequitable Access to Effective Cancer Treatment Around the World

Radiotheranostics are currently available to only a small number of cancer patients. Access is dependent on where the patient lives in the world and whether available treatments are approved and funded by national healthcare systems.

The majority of low- and middle-income countries do not have sufficient resources to respond to the needs of people living with cancer and provide life-saving innovative therapies.

In many cases, access to treatment depends on whether the patient has adequate private health insurance or his individual ability to pay for treatment.

In this context, chances of receiving radiotheranostics treatment vary significantly. Patients who could greatly benefit from this innovative technology are missing out.

At the Oncidium foundation, we are convinced that we can make a difference by connecting healthcare professionals and radioisotope companies and thus changing lives one patient at a time.

Introducing the RLT-Connect Online Platform

The RLT-Connect online platform brings together healthcare professionals and radioisotope companies with a single, common objective: join forces to end cancer care inequity. It allows to submit patient cases and requests for treatment donation for patients for whom all other options have been explored, and who meet qualifying criteria.

It will be launched **in 6 pilot countries** in 2023: Australia, Argentina, Brazil, Egypt, Mexico and Peru.

Healthcare professionnals

Submission of patient cases & requests for treatment donation

Radioisotope companies

Review of patient cases & decision on treatment donation

After the donation approval

- Importation process handled by the local radiopharmacy & labeling and QC provided pro bono or at operational cost only.
- Treatment delivered pro bono by the hospital as well as patient access to lab tests and PET or SPECT scans.

A Clearly Defined Governance: Roles & Responsibilities



Oncidium foundation

- Project facilitator connecting stakeholders
- Definition of patient eligibility criteria together with the Advisory Board & creation of an Ethical Charter
- Evaluation of requests before submission on the platform
- Search for donors to pay for costs



Healthcare Professionals and therapy centers

- Selection of patients and creation of paperwork for treatment access: early access, compassionate use, expanded access, etc.
- Submission of cases on online platform
- Feedback on treatment outcomes



Radioisotope Companies

- Commitment to provide the entire treatment plan for selected patients
- Definition of number of doses to be donated each year
- Creation of donation schedule

WHY PARTICIPATING AS A RADIOISOTOPE COMPANY?


- Join other industry leaders
- Enter new markets and recognition
- Improve access to medicines
- **I** Demonstrate ESG commitment
- I Generate real-world evidence (RWE)

A Shared Common Purpose: Changing Lives, One Patient at a Time

At the Oncidium foundation, patients are at the heart of everything we do. We work together to help them access the treatment they need.

In Argentina for example, we supported Fernando Acosta, a physician and war veteran, in his fight to access lutetium-177 PSMA treatment for prostate cancer. To make it happen, he gathered more than 70,000 signatures and called in our help and that of fellow physicians. His inspiring journey represents the core mission of the Oncidium foundation.

THE STORY OF FERNANDO ACOSTA, A HUSBAND, FATHER, GRAND-FATHER, WAR VETERAN AND PHYSICIAN



At the age of 55, in apparent perfect health and with 21 years of professional practice, I was diagnosed with a paraneoplastic syndrome, behind which was hidden an advanced prostate adenocarcinoma Gleason 9, non-surgical.

In 4 years and after 42 sessions of chemotherapy every 21 days, a protocol for three months that did not work, and radiotherapy, there was nothing left to try.

When I found out about the lutetium treatment, I did not care that it was impossible. In a few days, a whole ecosystem made the impossible possible. I focused and visualized lutetium diagnosing, irradiating, and eliminating every neoplastic cell in my body. After three doses and observing the scans without evidence of neoplastic focus in activity, tears of happiness ran on my cheeks and on all of those who believed in me and helped unconditionally.

Today I lead a group of patients with prostate cancer in treatment with lutetium. I am eternally grateful to the scientists who discovered the usefulness of this radionuclide, to the Oncidium foundation and to my treating physician Dr. María Bastianello whose humanity and dedication surprises me every day.

HOW DID IT HAPPEN?

- The Oncidium foundation intermediated a donation of ¹⁷⁷Lu-PSMA doses from a radioisotope company.
- The Argentinian radiopharmacy donated ¹⁷⁷Lu-PSMA labelling, QC and release, and F-PSMA-1007 for PET scanning.
- The hospital donated the administration and PET /SPECT scanning.

The Oncidium foundation has helped several other cancer patients benefift rom donated doses.

Together, we can continue making a difference for cancer patients and those who care for them.



Avenue Herrmann-Debroux, 40 1160 Brussels • Belgium contact@oncidium-life.org

www.oncidiumfoundation.org



>600
Registered
hospitals



>50
Global
ambassadors



Lives saved with your support

